Compare

medmix AG/Fr. MEDX

1D1W1MYTD1Y5YMAX

About medmix AG

medmix AG is a precision delivery device company operating primarily in the healthcare and industrial sectors. Its core business involves developing and manufacturing high-precision delivery devices used in a variety of applications, including healthcare, consumer, and industrial segments. The company offers a range of products such as drug delivery devices, dental applicators, and industrial mixing solutions. Headquartered in Switzerland, medmix has a global presence with a network that supports its diverse client base. The company focuses on leveraging its expertise in high-precision engineering to offer innovative solutions that meet specific industry needs.
Ticker
Fr. MEDX
Sector
Health
Primary listing
XSWX
Employees
2,587
Headquarters
Baar, Switzerland
Website
www.medmix.swiss

medmix AG Metrics

BasicAdvanced
CHF 403M
-
-CHF 0.00
0.82
CHF 0.10
1.01%

Bulls say / Bears say

Operational improvements are lifting profitability despite weaker volumes. In H1 2026, adjusted EBITDA margin rose for the fifth consecutive half-year to 20.3%, while free cash flow increased 4.6% and the company continued pursuing CHF33 million of savings. (medmix AG)
Healthcare is showing resilience and could support a recovery. H1 healthcare revenue grew organically, led by strong Surgery growth and solid Dental growth, while higher Beauty order intake supported management’s expectation of a stronger second half. (medmix AG)
New device platforms could deepen medmix’s role with pharmaceutical and dental customers. The D-Flex collaboration with Xeris targets a once-weekly hypothyroidism therapy, while the FleXa syringe platform adds a customisable dental product with multiple sizes and accessories. (TipRanks, StockTitan)
Top-line momentum remains weak. H1 revenue fell 1.6% organically, with Consumer & Industrial down 3.2%; Beauty volumes declined and Drug Delivery was hurt by customers moving to dual sourcing. (medmix AG, Quartr)
Reported earnings are still very thin and were hit by restructuring and impairment charges. H1 net income fell to about CHF0.8 million from CHF6.9 million, while EBIT dropped to CHF10.6 million, showing that the turnaround has not yet produced dependable statutory profits. (MarketScreener, RTTNews)
The recovery case depends on a sharp improvement from a low base. After the results, analysts cut their 2026 EPS forecasts materially, while projected revenue growth remained modest and below the wider industry’s expected pace. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

medmix AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

medmix AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing medmix AG

AllUSDEURGBP
Funds
Fund name
Fund size
Fr. MEDX weighting
Vanguard FTSE Global All-cap$VALU
$199M0.00%
Vanguard FTSE Global All-cap€VGLA
€171M0.00%
Vanguard FTSE Global All-cap£VALL
£147M0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.